Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 110.00
Bid: 109.60
Ask: 110.00
Change: -0.60 (-0.54%)
Spread: 0.40 (0.365%)
Open: 110.20
High: 110.80
Low: 109.60
Prev. Close: 110.60
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Omicron hope lifts FTSE despite UK virus surge

Wed, 22nd Dec 2021 17:03

(Alliance News) - Equity prices in London on Wednesday shook off news of fresh daily record coronavirus infections in the UK to end higher amid cautious optimism over the severity of the Omicron variant.

The FTSE 100 index closed up 44.25 points, or 0.6%, at 7,341.66. The FTSE 250 ended up 260.49 points, or 1.1%, at 23,080.79, and the AIM All-Share closed up 10.24 points, or 0.9%, at 1,183.81.

The Cboe UK 100 ended up 0.5% at 726.92, the Cboe UK 250 closed up 1.3% at 20478.57, and the Cboe Small Companies ended up 1.2% at 15004.11.

In European equities on Wednesday, the CAC 40 in Paris ended up 1.1% and the DAX 40 in Frankfurt ended up 1.0%.

Tentative optimism over the Omicron coronavirus variant supported markets on Wednesday.

"Some preliminary results from the UK Health & Security agency around the effects of the Omicron variant appear to be being received positively today. In line with South Africa's experience, it would appear that the Omicron variant does indeed appear to be milder, although the report also suggests that the higher infection rate could also place increased strain on hospitals, if enough people get it even if mortality is lower," said Michael Hewson, chief market analyst at CMC Markets.

"Nonetheless, it is still good news, and helps justify the move to delay a decision on new restrictions in England until after Christmas, and potentially allow greater leeway next week when restrictions could well change again."

UK Prime Minister Boris Johnson on Tuesday gave the go-ahead for people's Christmas plans, although he warned tougher restrictions could be implemented post-December 25.

However, Wales on Wednesday followed Scotland in unveiling new post-Christmas coronavirus curbs, primarily around hospitality and large events, as the UK's devolved nations move at different speeds to surging Omicron variant cases.

This came as the UK clocked another daily new cases record – 106,122 – as it announced it would buy millions of Covid pills, and also cut the isolation period for infected people from 10 to seven days with negative tests.

Sterling strengthened, however. The pound was quoted at USD1.3346 at the London equities close Wednesday, jumping from USD1.3248 at the close on Tuesday after some mixed gross domestic product data.

On the quarter before, UK gross domestic product advanced by 1.1% in the three months to September, slower than a 5.4% rise in the three months to July and missing consensus of an expansion of 1.3%, which would have matched the first estimate. On a year before, the UK economy grew by 6.8% in the third quarter, slightly beating the market forecast of 6.6% annual growth, which also would have matched the first estimate.

The ONS said the largest contributors to the increase in GDP were hospitality and arts, entertainment & recreation, following the further easing of restrictions and reopening of the economy during the period - something which could now be at risk given the Omicron wave.

Other countries have started to impose restrictions to curb the virus's spread. The Netherlands has already imposed a Christmas lockdown and Germany has slapped a limit of 10 people on private parties, closed nightclubs and banned spectators from major events including soccer matches.

Shaking this off, London-listed travel and leisure firms gained on Wednesday. Jet engine maker Rolls-Royce ended up 3.3% and Holiday Inn owner InterContinental Hotels Group rose 2.7%.

Pandemic-battered stocks also ended in the green in the mid-cap FTSE 250 index, with food and beverage outlets operator SSP Group rising 4.8% and Mitchells & Butlers up 2.7%.

Elsewhere, Taylor Wimpey rose 2.2% after committing to removing terms from contracts that double ground rents for leaseholders every 10 years.

Taylor Wimpey said the UK Competition & Markets Authority investigation into the historical sale of leasehold properties with doubling ground rent clauses by the company is closed, following the agreement of voluntary undertakings. The High Wycombe-based housebuilder said the cost of the undertakings falls within the original provision Taylor Wimpey made in 2017.

Syncona jumped 5.5% after the healthcare investor said its portfolio company Gyroscope Therapeutics will be sold to Swiss pharmaceutical maker Novartis for up to USD1.5 billion.

Syncona has a 54% stake in Gyroscope following a USD42 million investment in March, after co-founding the business in 2016. In a bumper payday, Syncona will receive upfront cash proceeds of GBP334 million from the deal, representing a GBP180 million uplift to the current holding value.

Stocks in New York were higher at the London equities close, with the DJIA up 0.5%, the S&P 500 index up 0.7%, and the Nasdaq Composite up 0.9%.

The dollar was on the back foot amid Wednesday's cautious optimism, failing to get a boost from an upwards revision to the US economy's performance in the third quarter.

On an annual basis, the US economy grew at a rate of 2.3% in the three months to September, slowing from a 6.7% expansion in the second quarter. The latest reading beat the market forecast of an expansion of 2.1%, however, which would have matched the second estimate.

The euro stood at USD1.1327 at the European equities close Wednesday, up against USD1.1267 at the same time on Tuesday.

Gold benefited from dollar weakness. The shining metal was quoted at USD1,797.90 an ounce at the London equities close Wednesday, rising from USD1,785.40 at the close on Tuesday.

However, the safe haven Japanese yen eased back. Against the yen, the dollar rose to JPY114.22 compared to JPY114.14 late Tuesday.

Brent oil was quoted at USD74.74 a barrel at the London equities close Wednesday, up from USD73.48 late Tuesday.

Thursday's economic calendar has German import prices at 0700 GMT and US initial jobless claims at 1330 GMT, alongside durable goods orders and core personal consumption expenditures due at the same time.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
11 May 2022 09:30

Syncona investee Freeline narrows quarterly loss as costs fall

(Alliance News) - Healthcare company investor Syncona Ltd on Wednesday noted that its portfolio company Freeline Therapeutics PLC trimmed its loss for the first quarter of 2022.

Read more
10 May 2022 14:26

IN BRIEF: Syncona investee Achilles widens quarterly loss on costs

Syncona Ltd - investor in healthcare companies - Notes investee company Achilles Therapeutics PLC posts widened loss amid rising research & development costs. Pretax loss in the quarter ended March 31 widens to USD17.3 million from USD13.8 million a year ago. Research & development costs surge to USD13.0 million from USD8.9 million, mainly due to increased activity in ongoing clinical trials. Cash and equivalents on March 31 fall to USD236.9 million from USD266.3 million as of December 31. "The company anticipates that its cash and cash equivalents are sufficient to fund its planned operations into the second half of 2024," Achilles says.

Read more
5 May 2022 12:59

IN BRIEF: Syncona's investee Autolus widens quarterly loss as costs up

Syncona Ltd - London-based healthcare & investment company - Reports quarterly loss for its portfolio company Autolus Therapeutics PLC as research costs rise. Net loss widens to USD42.7 million from USD39.0 million a year ago. Research & development expenses rise to USD34.0 million from USD30.7 million, Syncona explains.

Read more
28 Apr 2022 12:52

IN BRIEF: Syncona invests GBP15 million more in OMass Therapeutics

Syncona Ltd - London-based investment company - Invests more into OMass Therapeutics, an Oxford University biotechnology spin-out. After the new GBP15 million investment, Syncona now holds a 31% stake worth GBP44 million in the developer of small molecule drugs. The GBP15 million is part of an oversubscribed GBP75.5 million second round of funding for OMass, which now has raised GBP119 million in total.

Read more
28 Apr 2022 08:59

Syncona takes part in oversubscribed funding round for OMass

(Sharecast News) - Syncona committed further funding for rare-disease specialist OMass Therapeutics alongside a syndicate of investors which included a unit of French drug giant Sanofi.

Read more
11 Apr 2022 09:25

Syncona's investee Anaveon receives good trial data

(Alliance News) - Syncona Ltd on Monday noted that its portfolio company Anaveon AG received "encouraging" first clinical data from its ongoing phase I/II study for ANV419.

Read more
11 Apr 2022 07:49

Syncona's Anaveon to present first clinical data from ANV419 study

(Sharecast News) - Healthcare company Syncona said on Monday that its portfolio company, Anaveon AG, a clinical-stage immuno-oncology business, had announced that the first clinical data from the ongoing Phase I/II study of its lead programme, ANV419, would be presented in a poster at the American Association for Cancer Research's annual meeting in New Orleans.

Read more
1 Apr 2022 07:32

Syncona notes portfolio company Freeline annual loss widens in 2021

(Alliance News) - Syncona Ltd said on Friday that portfolio company Freeline Therapeutics Holdings PLC suffered a widened loss last year.

Read more
11 Mar 2022 08:44

Syncona to invest further USD20 million in Freeline Therapeutics

(Alliance News) - Syncona Ltd said on Friday that it agreed to invest USD20.0 million in Freeline Therapeutics Holdings PLC, as part of the investee's USD26.1 million American depositary shares offering.

Read more
18 Feb 2022 10:03

Syncona completes USD1.5 billion sale of Gyroscope to Novartis

(Alliance News) - Syncona Ltd on Friday said it has completed the sale of Gyroscope Therapeutics Holding PLC to Novartis AG.

Read more
10 Feb 2022 07:47

Syncona's Q3 a 'period of significant activity'

(Sharecast News) - Life sciences firm Syncona said on Thursday that the third quarter had been a "period of significant activity", with $674.0m raised by its portfolio and its third successful exit to date.

Read more
8 Feb 2022 20:38

IN BRIEF: Syncona's Freeline says FLT190 drug "well tolerated"

IN BRIEF: Syncona's Freeline says FLT190 drug "well tolerated"

Read more
22 Dec 2021 12:21

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

LONDON MARKET MIDDAY: Stocks edge higher ahead of US growth figures

Read more
22 Dec 2021 10:51

TOP NEWS SUMMARY: Novartis agrees to buy UK's Gyroscope Therapeutics

TOP NEWS SUMMARY: Novartis agrees to buy UK's Gyroscope Therapeutics

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.